Endostatin gene therapy inhibits intratumoral macrophage M2 polarization

Detalhes bibliográficos
Autor(a) principal: Foguer, Karen [UNIFESP]
Data de Publicação: 2016
Outros Autores: Braga, Marina de Souza [UNIFESP], Schatzmann Peron, Jean Pierre, Bortoluci, Karina Ramalho [UNIFESP], Bellini, Maria Helena [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1016/j.biopha.2016.01.035
https://repositorio.unifesp.br/handle/11600/56147
Resumo: Background: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice. Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used to analyze plasma and cell culture supernatant cytokines. Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines, including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1, declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 + CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the culture supernatants of the ES-treated group. Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role. However, aside from promoting interferon-g secretion and an effective T cell response, we show here that this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and thus favoring tumor elimination. (C) 2016 Elsevier Masson SAS. All rights reserved.
id UFSP_f5dacae35d20b47bdc848221b4936cf4
oai_identifier_str oai:repositorio.unifesp.br/:11600/56147
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Endostatin gene therapy inhibits intratumoral macrophage M2 polarizationRenal cell carcinomaEndostatinTumor-associated macrophagesBackground: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice. Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used to analyze plasma and cell culture supernatant cytokines. Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines, including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1, declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 + CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the culture supernatants of the ES-treated group. Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role. However, aside from promoting interferon-g secretion and an effective T cell response, we show here that this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and thus favoring tumor elimination. (C) 2016 Elsevier Masson SAS. All rights reserved.Univ Fed Sao Paulo, Div Nephrol, Sao Paulo, BrazilIPEN CNEN, Dept Biotechnol, Sao Paulo, BrazilUniv Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Biol Biol Sci, Sao Paulo, BrazilUniv Fed Sao Paulo, Div Nephrol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Biol Biol Sci, Sao Paulo, BrazilWeb of ScienceFAPESPCNPqCAPES/PNPDFAPESP: 2011/18703-2CNPq: 473102/2012-9Elsevier France-Editions Scientifiques Medicales Elsevier2020-07-22T13:23:17Z2020-07-22T13:23:17Z2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion102-111application/pdfhttp://dx.doi.org/10.1016/j.biopha.2016.01.035Biomedicine & Pharmacotherapy. Paris, v. 79, p. 102-111, 2016.10.1016/j.biopha.2016.01.035WOS000373527100014.pdf0753-3322https://repositorio.unifesp.br/handle/11600/56147WOS:000373527100014engBiomedicine & PharmacotherapyParisinfo:eu-repo/semantics/openAccessFoguer, Karen [UNIFESP]Braga, Marina de Souza [UNIFESP]Schatzmann Peron, Jean PierreBortoluci, Karina Ramalho [UNIFESP]Bellini, Maria Helena [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-11T10:25:00Zoai:repositorio.unifesp.br/:11600/56147Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-11T10:25Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
title Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
spellingShingle Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
Foguer, Karen [UNIFESP]
Renal cell carcinoma
Endostatin
Tumor-associated macrophages
title_short Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
title_full Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
title_fullStr Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
title_full_unstemmed Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
title_sort Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
author Foguer, Karen [UNIFESP]
author_facet Foguer, Karen [UNIFESP]
Braga, Marina de Souza [UNIFESP]
Schatzmann Peron, Jean Pierre
Bortoluci, Karina Ramalho [UNIFESP]
Bellini, Maria Helena [UNIFESP]
author_role author
author2 Braga, Marina de Souza [UNIFESP]
Schatzmann Peron, Jean Pierre
Bortoluci, Karina Ramalho [UNIFESP]
Bellini, Maria Helena [UNIFESP]
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Foguer, Karen [UNIFESP]
Braga, Marina de Souza [UNIFESP]
Schatzmann Peron, Jean Pierre
Bortoluci, Karina Ramalho [UNIFESP]
Bellini, Maria Helena [UNIFESP]
dc.subject.por.fl_str_mv Renal cell carcinoma
Endostatin
Tumor-associated macrophages
topic Renal cell carcinoma
Endostatin
Tumor-associated macrophages
description Background: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice. Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used to analyze plasma and cell culture supernatant cytokines. Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines, including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1, declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 + CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the culture supernatants of the ES-treated group. Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role. However, aside from promoting interferon-g secretion and an effective T cell response, we show here that this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and thus favoring tumor elimination. (C) 2016 Elsevier Masson SAS. All rights reserved.
publishDate 2016
dc.date.none.fl_str_mv 2016
2020-07-22T13:23:17Z
2020-07-22T13:23:17Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1016/j.biopha.2016.01.035
Biomedicine & Pharmacotherapy. Paris, v. 79, p. 102-111, 2016.
10.1016/j.biopha.2016.01.035
WOS000373527100014.pdf
0753-3322
https://repositorio.unifesp.br/handle/11600/56147
WOS:000373527100014
url http://dx.doi.org/10.1016/j.biopha.2016.01.035
https://repositorio.unifesp.br/handle/11600/56147
identifier_str_mv Biomedicine & Pharmacotherapy. Paris, v. 79, p. 102-111, 2016.
10.1016/j.biopha.2016.01.035
WOS000373527100014.pdf
0753-3322
WOS:000373527100014
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Biomedicine & Pharmacotherapy
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 102-111
application/pdf
dc.coverage.none.fl_str_mv Paris
dc.publisher.none.fl_str_mv Elsevier France-Editions Scientifiques Medicales Elsevier
publisher.none.fl_str_mv Elsevier France-Editions Scientifiques Medicales Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268389364858880